RINVOQ is an oral selective and reversible JAK inhibitor indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.1
One dose, one tablet,
once a day
Once-daily oral treatment for your adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy
Download the prescribing guide to get started
Dosing recommendations1
The recommended dose of RINVOQ in active AS is one 15-mg tablet once a day, with or without food
The tablet should be swallowed whole, and should not be split, crushed, or chewed
Take RINVOQ at the
same time every day
Upadacitinib is metabolized mainly by CYP3A4. Therefore, upadacitinib plasma exposures can be affected by medicinal products that strongly inhibit (e.g., ketoconazole, itraconazole, posaconazole, voriconazole, and clarithromycin) or induce (rifampin and phenytoin) CYP3A4. Consider alternatives to strong CYP3A4 inhibitors when used in the long term. Patients should be monitored for changes in disease activity if upadacitinib is co-administered with strong CYP3A4 inducers.
Discontinuation
Consideration should be given to discontinuing treatment in patients with ankylosing spondylitis who have shown no response after 16 weeks of treatment. Some patients with initial partial response may subsequently improve with continued treatment beyond 16 weeks.
Please consult the Summary of Product Characteristics for further details regarding monitoring requirements and contraindications prior to initiating RINVOQ.
You may also be interested in
I want to receive more information
via a product specialist.
I have a question for
Medical Information.
- RINVOQ [Summary of Product Characteristics]. AbbVie Deutschland GmbH & Co. KG.